On Air Now

Listen

Listen Live Now » 100.3 FM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
38° Feels Like: 38°
Wind: WSW 0 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Today

Sunny 68°

Tonight

Clear 46°

Tomorrow

Sunny 73°

Alerts

Novartis lung drug not inferior to GSK's Seretide, study shows

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013. REUTERS/Arnd Wiegmann
The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013. REUTERS/Arnd Wiegmann

ZURICH (Reuters) - Patients taking Novartis' inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline's Seretide, the Swiss drugmaker said on Friday, citing a late stage study.

Also known as QVA149, Onbrez Breezhaler belongs to a new type of dual-action treatments that are expected by analysts to become major sellers.

The Phase IV study in patients with moderate chronic obstructive pulmonary disease (COPD) found Novartis' once-daily drug showed similar benefits in reducing shortness of breath as GSK's Seretide, which must be taken twice daily.

Around 210 million people worldwide suffer from COPD, a disease that causes breathing trouble and chronic coughing, and is sometimes fatal.

(Reporting by Caroline Copley; Editing by Edwina Gibbs)

Comments